These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28214030)

  • 1. Re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44-5: Preclinical Combinatorial Approach to Enhance Radiotherapy Effects and Reduce its Morbidity May Be Tested in the Clinic.
    Vale S
    Eur Urol; 2017 Aug; 72(2):e32-e33. PubMed ID: 28214030
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Salvador Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44-5. Preclinical Combinatory Approach to Enhance Radiotherapy Effects and Reduce its Morbidity may be Tested in the Clinic: Wider Whole-pelvis Radiotherapy Fields and Enhanced Antitumoral Effect Mediated by T Lymphocytes: A Legitimate Hypothesis?
    Cozzarini C; Benigni F; Fiorino C; Mondino A; Di Muzio N
    Eur Urol; 2017 Aug; 72(2):e34-e35. PubMed ID: 28214033
    [No Abstract]   [Full Text] [Related]  

  • 3. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment?
    Cozzarini C
    Eur Urol; 2017 Jan; 71(1):44-45. PubMed ID: 27600590
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
    De Bari B; Alongi F; Arcangeli S
    Eur Urol; 2014 Dec; 66(6):e111-2. PubMed ID: 25190611
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's letter to the editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
    Cozzarini C; Fiorino C; Briganti A; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):e113-4. PubMed ID: 25199719
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's letter to the editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
    Abdollah F; Briganti A
    Eur Urol; 2013 Nov; 64(5):e103-4. PubMed ID: 23915876
    [No Abstract]   [Full Text] [Related]  

  • 7. Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2.
    Fiorino C; Briganti A; Cozzarini C
    Eur Urol; 2015 Mar; 67(3):e56-7. PubMed ID: 25466947
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Daniel E. Spratt, Herbert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71;37-43: High-dose Radiotherapy and Pelvic Lymph Nodal Irradiation for High-risk Prostate Cancer in the Image-guided Radiotherapy Era.
    Fodor A; Fiorino C; Picchio M; Di Muzio N
    Eur Urol; 2017 Jun; 71(6):e179-e180. PubMed ID: 28065538
    [No Abstract]   [Full Text] [Related]  

  • 9. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Chera BS; Vargas C; Morris CG; Louis D; Flampouri S; Yeung D; Duvvuri S; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):994-1002. PubMed ID: 19619961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
    Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Sung Kim, Shunhua Shen, Dirk F. Moore, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol 2011;60:908-16.
    Rossi CJ
    Eur Urol; 2012 May; 61(5):e43; author reply e44. PubMed ID: 22326675
    [No Abstract]   [Full Text] [Related]  

  • 13. Defining the "Hostile Pelvis" for Intensity Modulated Radiation Therapy: The Impact of Anatomic Variations in Pelvic Dimensions on Dose Delivered to Target Volumes and Organs at Risk in Patients With High-Risk Prostate Cancer Treated With Whole Pelvic Radiation Therapy.
    Yirmibeşoğlu Erkal E; Karabey S; Karabey A; Hayran M; Erkal HŞ
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):894-903. PubMed ID: 26104941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.
    Voog JC; Paulus R; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):212-3. PubMed ID: 26443430
    [No Abstract]   [Full Text] [Related]  

  • 15. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancer.
    You SH; Lee JY; Lee CG
    Yonsei Med J; 2015 Mar; 56(2):510-8. PubMed ID: 25684003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Options of hypofractionation of proton boost in locally advanced prostate cancer].
    Khmelevskiĭ EV; Pan'shin GA; Kancheli IN; Khoroshkov VS
    Vopr Onkol; 2012; 58(6):787-94. PubMed ID: 23600305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects.
    Sini C; Noris Chiorda B; Gabriele P; Sanguineti G; Morlino S; Badenchini F; Cante D; Carillo V; Gaetano M; Giandini T; Landoni V; Maggio A; Perna L; Petrucci E; Sacco V; Valdagni R; Rancati T; Fiorino C; Cozzarini C
    Radiother Oncol; 2017 Aug; 124(2):296-301. PubMed ID: 28739383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. Eur Urol 2016;69:58-9: Which patients need treatment intensification?
    Dal Pra A; Spahn M
    Eur Urol; 2016 Apr; 69(4):e74-e75. PubMed ID: 26508311
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.